Wall Street brokerages forecast that DexCom, Inc. (NASDAQ:DXCM) will report sales of $183.65 million for the current quarter, according to Zacks Investment Research. Eight analysts have provided estimates for DexCom’s earnings. The lowest sales estimate is $182.40 million and the highest is $185.80 million. DexCom reported sales of $148.60 million during the same quarter last year, which indicates a positive year over year growth rate of 23.6%. The business is scheduled to report its next earnings report on Tuesday, November 7th.

On average, analysts expect that DexCom will report full year sales of $183.65 million for the current year, with estimates ranging from $715.57 million to $732.90 million. For the next year, analysts forecast that the company will report sales of $947.15 million per share, with estimates ranging from $906.00 million to $969.70 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that follow DexCom.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Tuesday, August 1st. The medical device company reported ($0.16) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.07. The firm had revenue of $170.60 million for the quarter, compared to analysts’ expectations of $166.54 million. DexCom had a negative net margin of 10.27% and a negative return on equity of 27.90%. The firm’s revenue was up 24.3% on a year-over-year basis. During the same period in the prior year, the company earned ($0.24) EPS.

A number of equities analysts recently weighed in on DXCM shares. ValuEngine raised DexCom from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Canaccord Genuity reissued a “buy” rating and issued a $90.00 price target on shares of DexCom in a research note on Wednesday, June 7th. BidaskClub raised DexCom from a “sell” rating to a “hold” rating in a research note on Saturday, August 19th. TheStreet raised DexCom from a “d” rating to a “c-” rating in a research note on Wednesday, August 2nd. Finally, Piper Jaffray Companies reissued an “overweight” rating and issued a $78.00 price target on shares of DexCom in a research note on Monday, May 22nd. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $87.64.

COPYRIGHT VIOLATION WARNING: “DexCom, Inc. (DXCM) Expected to Announce Quarterly Sales of $183.65 Million” was originally posted by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright & trademark law. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/10/dexcom-inc-dxcm-expected-to-announce-quarterly-sales-of-183-65-million.html.

In other news, EVP Richard Doubleday sold 1,635 shares of the company’s stock in a transaction that occurred on Wednesday, August 23rd. The stock was sold at an average price of $75.26, for a total transaction of $123,050.10. Following the completion of the transaction, the executive vice president now directly owns 72,395 shares in the company, valued at $5,448,447.70. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Kevin R. Sayer sold 6,000 shares of the company’s stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $69.07, for a total value of $414,420.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 32,179 shares of company stock valued at $2,282,217. Corporate insiders own 1.70% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. Independent Portfolio Consultants Inc. increased its position in shares of DexCom by 0.4% during the second quarter. Independent Portfolio Consultants Inc. now owns 2,499 shares of the medical device company’s stock valued at $183,000 after purchasing an additional 9 shares during the period. Bbva Compass Bancshares Inc. increased its position in shares of DexCom by 1.9% during the second quarter. Bbva Compass Bancshares Inc. now owns 3,670 shares of the medical device company’s stock valued at $268,000 after purchasing an additional 69 shares during the period. Public Employees Retirement Association of Colorado increased its position in shares of DexCom by 0.4% during the second quarter. Public Employees Retirement Association of Colorado now owns 18,613 shares of the medical device company’s stock valued at $1,362,000 after purchasing an additional 83 shares during the period. King Luther Capital Management Corp increased its position in shares of DexCom by 0.7% during the first quarter. King Luther Capital Management Corp now owns 12,105 shares of the medical device company’s stock valued at $1,026,000 after purchasing an additional 90 shares during the period. Finally, Raymond James Financial Services Advisors Inc. increased its position in shares of DexCom by 0.8% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 18,077 shares of the medical device company’s stock valued at $1,532,000 after purchasing an additional 140 shares during the period.

Shares of DexCom (DXCM) opened at 71.26 on Friday. The firm’s market capitalization is $6.17 billion. DexCom has a 52 week low of $57.68 and a 52 week high of $94.79. The company has a 50-day moving average of $71.90 and a 200-day moving average of $74.32.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Get a free copy of the Zacks research report on DexCom (DXCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.